Nym: Funding, Investors & Team (Sep 2026)
Nym transforms revenue cycle management with direct-to-billing autonomous coding that reduces denials and operational expenses, accelerates payment-cycles and maximizes audit-readiness. Nym automatically identifies and captures every clinical aspect of a chart, understands what is relevant as well as what is the most accurate code to use. Nym assigns codes only for charts it fully understands – unhandled charts are returned for human coding. After a chart has been coded, Nym’s audit-trail view provides a clear explanation of the system’s reasoning behind its decision to assign a specific code. This allows for a quick understanding of the audit trail for validation, compliance and appeals’ basis.
Nym has raised $41.5M across 2 funding rounds on record, the most recent an undisclosed round of $25.0M announced in Jul 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nym Company Profile and Key Stats
Latest funding round on record: Jul 2021.
Nym Funding Rounds
Nym raised $16.5M in an undisclosed round announced in Oct 2020.
9 months later, an undisclosed round of $25.0M was announced in Jul 2021.
Nym Founders and Leadership Team
Contact details for the Nym team: 1 of 1 has an email address on file.
Start 14-day free trial →Nym Funding Compared to Other Biotechnology Startups
Nym's latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nym in Biotechnology and Tel Aviv
Companies Similar to Nym
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
Nym Funding FAQs
What does Nym do?
Nym transforms revenue cycle management with direct-to-billing autonomous coding that reduces denials and operational expenses, accelerates payment-cycles and maximizes audit-readiness. Nym automatically identifies and captures every clinical aspect of a chart, understands what is relevant as well as what is the most accurate code to use. Nym assigns codes only for charts it fully understands – unhandled charts are returned for human coding. After a chart has been coded, Nym’s audit-trail view provides a clear explanation of the system’s reasoning behind its decision to assign a specific code. This allows for a quick understanding of the audit trail for validation, compliance and appeals’ basis.
How much funding has Nym raised?
Nym has raised $41.5M across 2 rounds on record. The most recent is an undisclosed round of $25.0M announced in Jul 2021.
When did Nym last raise funding?
Nym's most recent funding round on record is an undisclosed round of $25.0M, announced in Jul 2021.
Who is the CEO of Nym?
Amihai Neiderman is listed as CEO at Nym.
Where is Nym headquartered?
Nym is based in Tel Aviv, Israel.
How many employees does Nym have?
Nym is in the 101-250 employee band.
How does Nym's funding compare to other Biotechnology startups?
Nym's latest round of $25.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Nym Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nym is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.